AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16641576 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg
Number of subjects: 53
Study 16641576 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 53
Study 14615736 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-visiting intervention with weekly visits by paraprofessionals for the first 8 weeks of life
Number of subjects: 140
Study 14615736 — intervention group
Group type: COMPARATOR
Intervention: Control group (LBW-T infants without intervention)
Number of subjects: 140
Study 14615736 — intervention group
Group type: EXPERIMENTAL
Intervention: LBW-T intervened infants
Number of subjects: 140
Study 10632407 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 IU of FSH
Number of subjects: 40
Study 10632407 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU of FSH
Number of subjects: 40
Study 10632407 — intervention group
Group type: COMPARATOR
Intervention: Control group (no FSH treatment)
Number of subjects: 40
Study 9010698 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (75 mg)
Number of subjects: 12
Study 9010698 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (200 mg) and Imipramine (75 mg) in combination
Number of subjects: 12
Study 9010698 — intervention group
Group type: COMPARATOR
Intervention: Entacapone (200 mg)
Number of subjects: 12
Study 1561287 — intervention group
Group type: EXPERIMENTAL
Intervention: Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)
Number of subjects: 23
Study 1561287 — intervention group
Group type: EXPERIMENTAL
Intervention: National Institute of Mental Health Global Obsessive-Compulsive Scale (NIMH-GOCS)
Number of subjects: 23
Study 1561287 — intervention group
Group type: EXPERIMENTAL
Intervention: SCL-90-Obsessive-Compulsive Subscale (SCL-90-OCS)
Number of subjects: 23
Study 3881105 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol 480 mg/day
Number of subjects: 10
Study 3881105 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 31356985 — intervention group
Group type: EXPERIMENTAL
Intervention: Active (a) tDCS
Number of subjects: 20
Study 31356985 — intervention group
Group type: COMPARATOR
Intervention: Sham (s) tDCS
Number of subjects: 20
Study 28490581 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-valent HPV vaccine
Number of subjects: 388
Study 28490581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study 27812717 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV/FTC/TDF
Number of subjects: 35
Study 27812717 — intervention group
Group type: COMPARATOR
Intervention: RAL/DRV/r
Number of subjects: 35
Study 24628705 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST)
Number of subjects: 85
Study 24628705 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance CST (MCST)
Number of subjects: 85
Study 24628705 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 85
Study 22713768 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) initiated in 97 children
Number of subjects: 141
Study 22713768 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline selenium (Se) levels
Number of subjects: 141
Study 22713768 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline zinc (Zn) levels
Number of subjects: 141
Study 22713768 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ART zinc levels
Number of subjects: 141
Study 22713768 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CD4%
Number of subjects: 141
Study 22713768 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HIV-RNA
Number of subjects: 141
Study 22713768 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ferritin
Number of subjects: 141
Study 22713768 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 141
Study 20404773 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Empowerment Intervention (HEI)
Number of subjects: 59
Study 20404773 — intervention group
Group type: COMPARATOR
Intervention: Weekly newsletter (comparison group)
Number of subjects: 59
Study 18523223 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered RCTs measuring patient-important outcomes
Number of subjects: 436
Study 18523223 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered RCTs measuring physiological and laboratory outcomes
Number of subjects: 436
Study 18523223 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered RCTs measuring surrogate outcomes
Number of subjects: 436
Study 18523223 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered RCTs measuring patient-important outcomes as primary or secondary outcomes
Number of subjects: 436
Study 15902161 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ExMI treatment
Number of subjects: 51
Study 15902161 — intervention group
Group type: COMPARATOR
Intervention: Sham ExMI treatment
Number of subjects: 51
Study 14522571 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMCs from FH patients
Number of subjects: 0
Study 14522571 — intervention group
Group type: EXPERIMENTAL
Intervention: FH serum
Number of subjects: 0
Study 14522571 — intervention group
Group type: COMPARATOR
Intervention: Control serum
Number of subjects: 0
Study 10903043 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial middle turbinate resection
Number of subjects: 1106
Study 10903043 — intervention group
Group type: COMPARATOR
Intervention: No partial middle turbinate resection
Number of subjects: 1106
Study 9131395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (800 mg/day for 2 months) + Interferon (9 Mu/week for 6 months)
Number of subjects: 20
Study 9131395 — intervention group
Group type: COMPARATOR
Intervention: Interferon (9 Mu/week for 6 months)
Number of subjects: 20
Study 1540493 — intervention group
Group type: EXPERIMENTAL
Intervention: Information provided by an academic representative during a short 'sales' interview.
Number of subjects: 101
Study 6374057 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF (cyclophosphamide, doxorubicin, and 5-fluorouracil)
Number of subjects: 187
Study 6374057 — intervention group
Group type: COMPARATOR
Intervention: CAF + CAMELEON (CAF alternating with cytosine arabinoside, methotrexate with leucovorin rescue, and oncovin)
Number of subjects: 187
Study 6374057 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF
Number of subjects: 187
Study 6374057 — intervention group
Group type: COMPARATOR
Intervention: CAMELEON
Number of subjects: 187
Study 6374057 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF-CAMELEON regimen
Number of subjects: 187
Study 6374057 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF-CAMELEON
Number of subjects: 187
Study 31587724 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced anesthetic technique with EEG guidance
Number of subjects: 88
Study 31587724 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 88
Study 29489921 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured safety huddle review of alarm data with discussions to reduce alarms
Number of subjects: 11308
Study 29489921 — intervention group
Group type: COMPARATOR
Intervention: Control units (no intervention)
Number of subjects: 11308
Study 26820762 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents with VLBW infants
Number of subjects: 403
Study 26820762 — intervention group
Group type: COMPARATOR
Intervention: Parents with term infants
Number of subjects: 403
Study 26820762 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 403
Study 25448437 — intervention group
Group type: COMPARATOR
Intervention: Control group (Gp 1) - one-off oral health education talk to parents
Number of subjects: 450
Study 25448437 — intervention group
Group type: EXPERIMENTAL
Intervention: Gp 2 - oral health education talk and parental toothbrushing training, reinforced every 6 months
Number of subjects: 450
Study 25448437 — intervention group
Group type: EXPERIMENTAL
Intervention: Gp 3 - semi-annual application of fluoride varnish in addition to Gp 2 intervention
Number of subjects: 450
Study 22252363 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% poultry offal meal (OM) diet from 1 to 42 days
Number of subjects: 720
Study 22252363 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable diet (VD) from 1 to 21 days and 8% OM diet from 22 to 42 days
Number of subjects: 720
Study 22252363 — intervention group
Group type: EXPERIMENTAL
Intervention: VD from 1 to 35 days and 8% OM diet from 36 to 42 days
Number of subjects: 720
Study 22252363 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% OM diet from 1 to 21 days and VD from 22 to 42 days
Number of subjects: 720
Study 22252363 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% OM diet from 1 to 35 days and VD from 36 to 42 days
Number of subjects: 720
Study 22252363 — intervention group
Group type: COMPARATOR
Intervention: Vegetable diet (VD) from 1 to 42 days
Number of subjects: 720
Study 20380654 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial subcutaneous bolus of 1.4 U
Number of subjects: 10
Study 20380654 — intervention group
Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion without initial bolus
Number of subjects: 10
Study 17666472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet hydrochloride (30 mg twice daily to 90 mg four times daily) for 16 weeks
Number of subjects: 29
Study 17666472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet hydrochloride
Number of subjects: 29
Study 11069438 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl‐L‐carnitine hydrochloride (1 g)
Number of subjects: 24
Study 11069438 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl‐L‐carnitine hydrochloride (8 g)
Number of subjects: 24
Study 11069438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9308584 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic balloon angioplasty (PTA)
Number of subjects: 0
Study 9308584 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 0
Study 8369579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin 5 mg/kg/day
Number of subjects: 76
Study 8369579 — intervention group
Group type: COMPARATOR
Intervention: Etretinate 0.75 reduced to 0.5 mg/kg/day
Number of subjects: 76
Study 8369579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin maintenance therapy 2.5‐5 mg/kg/day
Number of subjects: 76
Study 3538936 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine 0.3 mg kg‐1
Number of subjects: 40
Study 3538936 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 40
Study 29482397 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-pulsed 532-nm/1064-nm QS laser treatment
Number of subjects: 10
Study 29482397 — intervention group
Group type: COMPARATOR
Intervention: Single-pulsed 1064-nm Nd:YAG laser treatment
Number of subjects: 10
Study 27504890 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour PIVC online course followed by an 8-hour live training course using simulation tools
Number of subjects: 0
Study 27504890 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group receiving the same intervention after crossover
Number of subjects: 0
Study 24304551 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin (20 mg 12 hours before coronary angiography + 20 mg immediately before PCI)
Number of subjects: 445
Study 24304551 — intervention group
Group type: COMPARATOR
Intervention: PCI without statin therapy (control group)
Number of subjects: 445
Study 24304551 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin (20 mg twice a day)
Number of subjects: 445
Study 22394023 — intervention group
Group type: EXPERIMENTAL
Intervention: Airborne-particle abraded dowels stored dry
Number of subjects: 60
Study 22394023 — intervention group
Group type: EXPERIMENTAL
Intervention: Dowels stored for 24 hours in aqueous solution at 37°C
Number of subjects: 60
Study 22394023 — intervention group
Group type: EXPERIMENTAL
Intervention: Airborne-particle abraded dowels followed by 24-hour aqueous storage at 37°C
Number of subjects: 60
Study 22394023 — intervention group
Group type: EXPERIMENTAL
Intervention: Dowels stored for 30 days in aqueous solution at 37°C
Number of subjects: 60
Study 22394023 — intervention group
Group type: EXPERIMENTAL
Intervention: Airborne-particle abraded dowels followed by 30-day aqueous storage at 37°C
Number of subjects: 60
Study 22394023 — intervention group
Group type: COMPARATOR
Intervention: Dry control group
Number of subjects: 60
Study 19706212 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid supplements (IFA; 60 mg Fe, 500 microg folic acid)
Number of subjects: 102
Study 19706212 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaf concentrate (LC; 5 mg Fe, 13 microg folic acid)
Number of subjects: 102
Study 18958549 — intervention group
Group type: EXPERIMENTAL
Intervention: FSSG scores in patients with reflux esophagitis
Number of subjects: 470
Study 18958549 — intervention group
Group type: COMPARATOR
Intervention: FSSG scores in relation to hiatal hernia presence
Number of subjects: 470
Study 18958549 — intervention group
Group type: COMPARATOR
Intervention: FSSG scores in relation to cardiac sphincter laxity (valve factor)
Number of subjects: 470
Study 15706071 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Ergonomics Training (AET)
Number of subjects: 87
Study 12535042 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 53
Study 12535042 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 53
Study 12535042 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and Propofol
Number of subjects: 53
Study 10759035 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered educational intervention
Number of subjects: 966
Study 10759035 — intervention group
Group type: COMPARATOR
Intervention: Standard HIV testing and counseling protocol
Number of subjects: 966
Study 10759035 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPD status
Number of subjects: 966
Study 10759035 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression status
Number of subjects: 966
Study 8947790 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 23
Study 1379660 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% pentastarch (group P)
Number of subjects: 90
Study 1379660 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% albumin (group A)
Number of subjects: 90
Study 1379660 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (group C)
Number of subjects: 90
Study 30604047 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 0
Study 27869293 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally relevant cancer education program combined with navigation services
Number of subjects: 705
Study 27869293 — intervention group
Group type: COMPARATOR
Intervention: General health education including information about cervical cancer risk and screening
Number of subjects: 705
Study 26483333 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib (250 mg orally twice daily)
Number of subjects: 28
Study 26483333 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (docetaxel 75 mg/m2 every three weeks)
Number of subjects: 28
Study 23672993 — intervention group
Group type: EXPERIMENTAL
Intervention: AHR-guided treatment strategy
Number of subjects: 137
Study 23672993 — intervention group
Group type: COMPARATOR
Intervention: Usual care by paediatrician and general practitioner
Number of subjects: 137
Study 23672993 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 137
Study 23672993 — intervention group
Group type: EXPERIMENTAL
Intervention: AHR measurement
Number of subjects: 137
Study 21719901 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO solution (1.2 g CHO/kg body mass)
Number of subjects: 12
Study 21719901 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-PRO solution (1.2 g CHO/kg body mass and 0.4 g PRO/kg body mass)
Number of subjects: 12
Study 21719901 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 12
Study 19574255 — intervention group
Group type: EXPERIMENTAL
Intervention: FC‐sIPPV
Number of subjects: 10
Study 19574255 — intervention group
Group type: COMPARATOR
Intervention: TC‐sIPPV
Number of subjects: 10
Study 18490279 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 937
Study 18490279 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol-based treatment
Number of subjects: 937
Study 16020559 — intervention group
Group type: EXPERIMENTAL
Intervention: MR angiography
Number of subjects: 157
Study 16020559 — intervention group
Group type: COMPARATOR
Intervention: CT angiography
Number of subjects: 157
Study 12450926 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase for thrombolysis
Number of subjects: 0
Study 12450926 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of thrombolysis
Number of subjects: 0
Study 10638397 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis using impedance quotients (F2/R), weight, and gestational age as variables.
Number of subjects: 24
Study 10638397 — intervention group
Group type: COMPARATOR
Intervention: Weight alone as a predictive model.
Number of subjects: 24
Study 7490363 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily application of UVA/UVB sunscreen for 24 months
Number of subjects: 46
Study 7490363 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 46
Study 1780566 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurate performance information
Number of subjects: 36
Study 1780566 — intervention group
Group type: EXPERIMENTAL
Intervention: False information that they lifted more than their actual lift
Number of subjects: 36
Study 1780566 — intervention group
Group type: EXPERIMENTAL
Intervention: False information that they lifted less than their actual lift
Number of subjects: 36
Study 1780566 — intervention group
Group type: EXPERIMENTAL
Intervention: Past weightlifting performance
Number of subjects: 36
Study 7074241 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine methonitrate 1.5 mg
Number of subjects: 0
Study 7074241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30418214 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (32 mg IV)
Number of subjects: 13
Study 30418214 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (32 mg IV)
Number of subjects: 13
Study 30418214 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone and Buprenorphine compared with placebo
Number of subjects: 13
Study 30418214 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone
Number of subjects: 13
Study 28248888 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar pulsed radiofrequency (PRF)
Number of subjects: 50
Study 28248888 — intervention group
Group type: COMPARATOR
Intervention: Monopolar pulsed radiofrequency (PRF)
Number of subjects: 50
Study 26007260 — intervention group
Group type: EXPERIMENTAL
Intervention: Pylorus Preserving Pancreaticoduodenectomy (PPPD)
Number of subjects: 0
Study 26007260 — intervention group
Group type: COMPARATOR
Intervention: Standard Whipple's Procedure (SW)
Number of subjects: 0
Study 23660462 — intervention group
Group type: EXPERIMENTAL
Intervention: HGHH curriculum
Number of subjects: 139
Study 23660462 — intervention group
Group type: EXPERIMENTAL
Intervention: HGHH curriculum (attending >1 class)
Number of subjects: 139
Study 23660462 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 139
Study 21843830 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program (30 minutes per session, 3 sessions per week for 8 weeks)
Number of subjects: 51
Study 21843830 — intervention group
Group type: COMPARATOR
Intervention: Usual activity (control group)
Number of subjects: 51
Study 19679578 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 60
Study 19679578 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression
Number of subjects: 60
Study 19679578 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 60
Study 17852370 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking vision
Number of subjects: 0
Study 17852370 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking touch
Number of subjects: 0
Study 17852370 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking audition
Number of subjects: 0
Study 17852370 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking olfaction
Number of subjects: 0
Study 15510361 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0-mm locking plates
Number of subjects: 90
Study 15510361 — intervention group
Group type: COMPARATOR
Intervention: 2.0-mm standard plates
Number of subjects: 90
Study 11555383 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) at approximately half the microgram dose for 6 months
Number of subjects: 133
Study 11555383 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 133
Study 11555383 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) or Budesonide (BUD)
Number of subjects: 133
Study 9814422 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbo‐FLAIR imaging
Number of subjects: 20
Study 9814422 — intervention group
Group type: COMPARATOR
Intervention: Gadolinium‐enhanced imaging
Number of subjects: 20
Study 9814422 — intervention group
Group type: EXPERIMENTAL
Intervention: T2‐weighted imaging
Number of subjects: 20
Study 7886393 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg once daily)
Number of subjects: 18
Study 7886393 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg once daily)
Number of subjects: 18
Study 7886393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3126527 — intervention group
Group type: EXPERIMENTAL
Intervention: R 58 735 (5 mg b.i.d. for 2 days followed by 10 mg b.i.d. for 5 days)
Number of subjects: 0
Study 3126527 — intervention group
Group type: EXPERIMENTAL
Intervention: R 58 735
Number of subjects: 0
Study 3126527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29310605 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologist training and patient communication aid
Number of subjects: 192
Study 29310605 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 192